BIT
BCLI

BlackRock Institutional Trust’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

BlackRock Institutional Trust’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$63K Hold
1,653
– – ﹤0.01% 3688
2016
Q3 		$60K Hold
1,653
– – ﹤0.01% 3737
2016
Q2 		$60K Hold
1,653
– – ﹤0.01% 3751
2016
Q1 		$66K Hold
1,653
– – ﹤0.01% 3762
2015
Q4 		$71K Hold
1,653
– – ﹤0.01% 3785
2015
Q3 		$57K Hold
1,653
– – ﹤0.01% 3794
2015
Q2 		$89K Buy
+1,653
New +$98.5K ﹤0.01% 3735

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock Institutional Trust's BCLI Position: Q4 2016 in Review

BlackRock Institutional Trust held its BRAINSTORM CELL THERAPUTC (BCLI) position steady in Q4 2016 at 1,653 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

BlackRock Institutional Trust first reported a position in BCLI in Q2 2015 and has held it in 7 quarters since. The position peaked at $89K in Q2 2015. 27 funds tracked by Wall St. Rank hold BCLI as of Q4 2016.

  • BlackRock Institutional Trust held 1,653 shares of BRAINSTORM CELL THERAPUTC worth $63K as of Q4 2016.
  • BlackRock Institutional Trust left its BRAINSTORM CELL THERAPUTC share count unchanged in Q4 2016.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3688 holding.
  • BlackRock Institutional Trust first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Institutional Trust's BRAINSTORM CELL THERAPUTC position peaked at $89K in Q2 2015.
  • 27 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.